Developer docs
API playgroundTry for free, no card

Search company profiles

Longenesis

Full company profile

uuid0002ql3

Namestring
Longenesis
Legal namestring
SIA Longenesis
Websiteurl
longenesis.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Longenesis (legal entity SIA Longenesis, headquartered at Dzirnavu iela 41a-5, Riga, Latvia) is a private health-technology SaaS company founded around 2017 that builds digital platforms for biomedical research and patient engagement. Its two flagship products are Engage, a patient engagement platform offering dynamic consent, e-consent, screening tools, PROMs/PREMs surveys, risk stratification calculators, and patient diaries; and Curator, a biomedical research acceleration platform that lets biobanks, hospitals, registries, and biotech companies publish anonymized metadata and enables real-time patient cohort identification against inclusion/exclusion criteria. The technology stack is cloud-based and certified to ISO/IEC 27001 and ISO/IEC 27701 with full GDPR compliance, positioning the product for regulated healthcare environments.

The company sells tiered annual and multi-year SaaS subscriptions alongside project-based engagements, with a freemium nonprofit onboarding funnel for Curator and a direct enterprise sales motion. Target customers span biopharma and biotech (Medtronic, Gedeon Richter, Ewopharma, Dante Genomics), biobanks and registries, hospitals and academic medical centers (Children's Clinical University Hospital Latvia, Pauls Stradins Clinical University Hospital, Riga Stradins University, Latvian BMC), and national health programs — most prominently the M42 Health Emirati Genome Programme in the UAE, which has engaged 500,000+ citizens since 2020. Distribution combines direct enterprise sales, partnership-led co-development with biopharma and genomics players, and self-service Curator registration, supported by AWS infrastructure and an EIT Health partnership.

To date Longenesis has raised approximately $1.3 million across a $1.2 million late seed round in June 2021 led by Rustam Gilfanov and a $100,000 Supernova Challenge grant in October 2024, with no Series A disclosed. Its growth strategy relies heavily on EU Cohesion Policy and Latvia Recovery and Resilience Facility-funded co-development projects (cardiometabolic, Type 1 diabetes via DiaBuddy, cardiology, rare skin disease) alongside commercial contracts, keeping headcount in the 11–50 range while expanding its therapeutic-area focus and geographic footprint across the Baltics, Central and Eastern Europe, the Mediterranean, and the Middle East.

Short descriptiontext

Longenesis is a Latvian health-tech SaaS provider offering Engage (patient engagement and dynamic consent) and Curator (anonymized biomedical data discovery) platforms to biopharma, biobanks, hospitals, and medical device companies across Europe and the Middle East, enabling cohort identification and real-world evidence generation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRiga, Latvia
HQ citystring
Riga
HQ countrystring
Latvia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial platforms, patient engagement software, biomedical data management, digital consent solutions, healthcare research tools
Industry2 codes
PRIMARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLALABAJ
Patient Engagement, Education & Messaging Platforms (portal/CRM integrated)
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Clinical Trial Technology / Healthcare Research Software
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Subscriptions
TypeSubscription Recurring
Description

Longenesis operates as a SaaS company offering subscription-based access to its Engage and Curator platforms. The revenue model involves tiered pricing for different user roles (Data Publisher, Collaborator, or both) with annual or multi-year subscription contracts typical for enterprise customers.

longenesis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Free Trial for Nonprofits
ModelFreemiumBilling cadenceMonthly
Notes

Nonprofit health service providers can apply for a free trial covering one department of up to 100 participants. This serves as an entry point to convert customers into paid subscriptions.

longenesis.com
2Data Publisher Plan
ModelSubscriptionBilling cadenceAnnual
Notes

Unlimited anonymised dataset upload, technical support on dataset upload, incoming collaboration requests from potential partners & sponsors, tailored onboarding. Free registration available.

longenesis.com
3Collaborator Plan
ModelSubscriptionBilling cadenceAnnual
Notes

Access to published anonymised datasets, advanced query section to select patient cohorts/groups based on specific criteria, send collaboration requests to data publishers. Free registration for demo.

longenesis.com
4Data Publisher and Collaborator Plan
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Full access to Curator platform combining both Data Publisher and Collaborator capabilities. Pricing details to be provided by team after contact.

longenesis.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Engage
Description

Digital patient engagement platform for research execution, consent management, patient onboarding, surveys, screening, and feedback activities.

longenesis.com
+1 more record
Core offering1 text field

Longenesis provides a dual SaaS platform ecosystem for biomedical research and patient engagement. Engage is a digital patient engagement platform offering dynamic consent management, surveys, screening, PROMs/PREMs collection, patient diaries, and risk stratification tools. Curator is a biomedical research acceleration platform that lets biobanks, registries, and hospitals publish anonymised dataset metadata and enables researchers to query, identify patient cohorts, and request collaborations in real time, while preserving patient privacy and GDPR compliance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 500,000+ citizens participated in Emirati Genome Programme with Longenesis tools since 2020, expected to reach 1 million by 2025
+2 more records
Product overview1 text field

Longenesis is a SaaS company offering a digital platform for post-market research and patient engagement that bridges life-science companies, healthcare providers, and patients. The product portfolio consists of two flagship platforms: Engage and Curator. Engage is a patient engagement platform providing tools for e-consent, digital surveys, screening, patient-reported outcomes (PROMs/PREMs), patient identification, registries, and before/after visit monitoring. Curator is a biomedical research acceleration platform enabling data publishers (biobanks, hospitals, registries) to publish anonymised metadata for collaboration discovery, and allowing collaborators (researchers, pharma sponsors) to query and request access to datasets. These platforms are designed to be complementary—Curator serves as a mechanism for prospective data generation and cohort identification, while Engage facilitates direct patient engagement and data collection.

Product and service3 records
1Curator
CategoryBiomedical data discovery and collaboration platform
Description

Biomedical research acceleration platform that enables clinical investigators, patient organisations, registries, and biobanks to publish anonymised dataset metadata and showcase the scope of their data for research without compromising patient privacy. Collaborators can browse anonymised datasets, run advanced queries by inclusion/exclusion criteria, identify patient cohorts in real time, and send collaboration requests to data publishers. Targeted at biobanks, registries, hospitals, biopharma, and academic researchers.

2Engage
CategoryClinical trial and patient engagement platform
Description

Digital patient engagement and clinical research execution platform providing disease-specific tools including dynamic consent management, e-consent, surveys, screening and feedback activities, risk stratification calculators, patient diaries, reminders, and PROMs/PREMs collection. Designed to enable proactive engagement of patients and population cohorts in clinical research, market access, and adherence programs for biopharma, medical device, hospital, and academic customers.

3skrinings.lv
CategoryConsumer health screening platform
Description

Online health platform developed by Longenesis specialists that empowers individuals to learn about their health, particularly breast cancer risks and contraception methods, through tools such as a breast cancer risk assessment test. Integrates with Dante Genomics to offer discounted whole genome sequencing. Targeted at individual consumers seeking self-administered health screening.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Partnership to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants across the Baltics and Mediterranean regions. Dante Genomics provides at-home blood collection kits for WGS and genomic reports, while Longenesis enriches its digital educational engagement platform with discounted Dante offerings. The collaboration aims to make personalized medicine more mainstream across Europe.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Partnership with M42 Health for the Emirati Genome Programme aims to create one of the world's largest patient biobanks. Longenesis provides digital tools for participant engagement and consent-driven medical research, while M42 Health contributes AI-powered healthcare capabilities and genomic sequencing expertise. The collaboration supports UAE's national genome initiative with over 500,000 citizens participating since 2020.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Medtronic for implementing patient engagement solutions. Longenesis tools have impacted the speed of patient enrolment while complying with highest requirements of safety, data protection and participant-centricity. The partnership focuses on market access and patient enrollment for medical device research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Swiss pharmaceutical company Ewopharma for observational multicenter clinical trial into respiratory tract infections in children. Longenesis provides digital engagement tool, e-consent, patient diary and reminder functionality through its Engage platform to streamline data collection for investigators and participants' parents.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Hungarian pharmaceutical company Gedeon Richter for Real-World Data study on contraception. Longenesis.Curator platform enabled quick patient identification fitting inclusion criteria within existing cohort and immediate invitation sending for study participation.

6Riga Technical University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership with Riga Technical University for cardiometabolic disease digital platform project. EU Cohesion Policy funded project 1.1.1.3/1/24/A/090 developing cloud-based module for cardiometabolic disease prevention and early diagnosis.

longenesis.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ongoing research collaboration with Pauls Stradiņš Clinical University Hospital on multiple projects including cardiometabolic disease prevention platform and DiaBuddy digital assistant for Type 1 diabetes patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with MEDON for developing modular digital platform for clinical observations and research in cardiology. Project F-DIGIT-4 focuses on study design creation, patient engagement, and data analysis functionality.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term collaboration for patient surveys, long COVID symptom tracking in children, and PREM data gathering. Hospital has been using Longenesis digital tools for over a year with positive feedback on availability, speed, and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for Myasthenia gravis digital registry transformation and other research projects including rare skin diseases registry with Department of Atomic Physics and Spectroscopy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Castor is a direct competitor offering an eClinical platform for decentralized and hybrid clinical trials, including eConsent, ePRO, and remote data capture. It overlaps directly with Longenesis Engage on patient engagement and consent management in clinical research.

TypeDirect peer
Description

Medable provides a decentralized clinical trial platform with eCOA, eConsent, telehealth, and patient engagement tools. It competes head-to-head with Longenesis Engage for the same life sciences and CRO buyers running modern clinical studies.

TypeDirect peer
Description

Signant Health specializes in clinical trial patient engagement, eCOA, ePRO, and rater training. Its product set directly competes with Longenesis Engage for pharma and CRO customers running patient-centric studies.

TypeBroad incumbent
Description

Veeva offers a broad suite of cloud software for life sciences, including Vault Clinical (EDC, CTMS, eTMF) and CRM. It is a broad incumbent whose Vault platform can absorb functionality that overlaps with both Engage and Curator.

TypeBroad incumbent
Description

Medidata is a leading clinical trials technology platform covering EDC, CTMS, eCOA, randomization, and trial design. It is a broad incumbent whose Rave platform competes with Longenesis across the full clinical operations stack.

TypeDirect peer
Description

TriNetX operates a global health research network that enables cohort identification and real-world data queries for clinical trial feasibility. It is the most direct competitor to Longenesis Curator for sponsor and CRO cohort discovery.

TypeBroad incumbent
Description

Oracle's Clinical One platform is a unified clinical trial suite covering EDC, RTSM, eCOA, and patient engagement. It competes as a broad incumbent offering an end-to-end alternative to Longenesis's two-product approach.

TypeEmerging player
Description

Y-Prime provides clinical trial technology, including IRT, eCOA, and patient engagement tools, focused on simplifying trial operations. It is an emerging peer with overlapping capabilities to Longenesis Engage in the patient engagement and data collection layer.

TypeBroad incumbent
Description

IQVIA combines clinical research services with technology platforms (e.g., EDC, eCOA, real-world data) and operates a large healthcare data network. It is a broad incumbent whose analytics and data network partially overlap with Curator's data discovery use cases.

TypeEmerging player
Description

Florence Healthcare provides an eRegulatory and site document management platform for clinical trials. While narrower than Longenesis, it competes in the same site- and study-management buying cycle that Longenesis targets with its research workflow tools.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Longenesis

Clinical Trial Technology / Healthcare Research Softwarelongenesis.com

Longenesis is a Latvian health-tech SaaS provider offering Engage (patient engagement and dynamic consent) and Curator (anonymized biomedical data discovery) platforms to biopharma, biobanks, hospitals, and medical device companies across Europe and the Middle East, enabling cohort identification and real-world evidence generation.

What Longenesis does

Longenesis (legal entity SIA Longenesis, headquartered at Dzirnavu iela 41a-5, Riga, Latvia) is a private health-technology SaaS company founded around 2017 that builds digital platforms for biomedical research and patient engagement. Its two flagship products are Engage, a patient engagement platform offering dynamic consent, e-consent, screening tools, PROMs/PREMs surveys, risk stratification calculators, and patient diaries; and Curator, a biomedical research acceleration platform that lets biobanks, hospitals, registries, and biotech companies publish anonymized metadata and enables real-time patient cohort identification against inclusion/exclusion criteria. The technology stack is cloud-based and certified to ISO/IEC 27001 and ISO/IEC 27701 with full GDPR compliance, positioning the product for regulated healthcare environments.

The company sells tiered annual and multi-year SaaS subscriptions alongside project-based engagements, with a freemium nonprofit onboarding funnel for Curator and a direct enterprise sales motion. Target customers span biopharma and biotech (Medtronic, Gedeon Richter, Ewopharma, Dante Genomics), biobanks and registries, hospitals and academic medical centers (Children's Clinical University Hospital Latvia, Pauls Stradins Clinical University Hospital, Riga Stradins University, Latvian BMC), and national health programs — most prominently the M42 Health Emirati Genome Programme in the UAE, which has engaged 500,000+ citizens since 2020. Distribution combines direct enterprise sales, partnership-led co-development with biopharma and genomics players, and self-service Curator registration, supported by AWS infrastructure and an EIT Health partnership.

To date Longenesis has raised approximately $1.3 million across a $1.2 million late seed round in June 2021 led by Rustam Gilfanov and a $100,000 Supernova Challenge grant in October 2024, with no Series A disclosed. Its growth strategy relies heavily on EU Cohesion Policy and Latvia Recovery and Resilience Facility-funded co-development projects (cardiometabolic, Type 1 diabetes via DiaBuddy, cardiology, rare skin disease) alongside commercial contracts, keeping headcount in the 11–50 range while expanding its therapeutic-area focus and geographic footprint across the Baltics, Central and Eastern Europe, the Mediterranean, and the Middle East.

Longenesis firmographics

Firmographics
Name
Longenesis
Legal name
SIA Longenesis
Website
https://longenesis.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Longenesis is a Latvian health-tech SaaS provider offering Engage (patient engagement and dynamic consent) and Curator (anonymized biomedical data discovery) platforms to biopharma, biobanks, hospitals, and medical device companies across Europe and the Middle East, enabling cohort identification and real-world evidence generation.
Ownership category
akta.pro rank

Longenesis industry classification

Industry
Product category
Clinical Trial Technology / Healthcare Research Software
NAICS
Software Publishers (513210)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLALABAJ
Patient Engagement, Education & Messaging Platforms (portal/CRM integrated)
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Clinical trial platforms
  • Patient engagement software
  • Biomedical data management
  • Digital consent solutions
  • Healthcare research tools

Where Longenesis is headquartered

Location

Headquarters

HQ city
Riga
HQ country
Latvia
HQ region
Europe

Offices1 record

Markets served

Longenesis business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. SaaS Platform Subscriptions: Longenesis operates as a SaaS company offering subscription-based access to its Engage and Curator platforms. The revenue model involves tiered pricing for different user roles (Data Publisher, Collaborator, or both) with annual or multi-year subscription contracts typical for enterprise customers.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree Trial for Nonprofits
SubscriptionAnnualData Publisher Plan
SubscriptionAnnualCollaborator Plan
SubscriptionMulti-year contractData Publisher and Collaborator Plan

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Longenesis product offering

Product offering

Core offering

Longenesis provides a dual SaaS platform ecosystem for biomedical research and patient engagement. Engage is a digital patient engagement platform offering dynamic consent management, surveys, screening, PROMs/PREMs collection, patient diaries, and risk stratification tools. Curator is a biomedical research acceleration platform that lets biobanks, registries, and hospitals publish anonymised dataset metadata and enables researchers to query, identify patient cohorts, and request collaborations in real time, while preserving patient privacy and GDPR compliance.

Product overview

Longenesis is a SaaS company offering a digital platform for post-market research and patient engagement that bridges life-science companies, healthcare providers, and patients. The product portfolio consists of two flagship platforms: Engage and Curator. Engage is a patient engagement platform providing tools for e-consent, digital surveys, screening, patient-reported outcomes (PROMs/PREMs), patient identification, registries, and before/after visit monitoring. Curator is a biomedical research acceleration platform enabling data publishers (biobanks, hospitals, registries) to publish anonymised metadata for collaboration discovery, and allowing collaborators (researchers, pharma sponsors) to query and request access to datasets. These platforms are designed to be complementary—Curator serves as a mechanism for prospective data generation and cohort identification, while Engage facilitates direct patient engagement and data collection.

Differentiator

Problem solved

Functional benefit

Brands

  • Engage: Digital patient engagement platform for research execution, consent management, patient onboarding, surveys, screening, and feedback activities.
  • Curator

Products and services

  • Curator Biomedical research acceleration platform that enables clinical investigators, patient organisations, registries, and biobanks to publish anonymised dataset metadata and showcase the scope of their data for research without compromising patient privacy. Collaborators can browse anonymised datasets, run advanced queries by inclusion/exclusion criteria, identify patient cohorts in real time, and send collaboration requests to data publishers. Targeted at biobanks, registries, hospitals, biopharma, and academic researchers.
  • Engage Digital patient engagement and clinical research execution platform providing disease-specific tools including dynamic consent management, e-consent, surveys, screening and feedback activities, risk stratification calculators, patient diaries, reminders, and PROMs/PREMs collection. Designed to enable proactive engagement of patients and population cohorts in clinical research, market access, and adherence programs for biopharma, medical device, hospital, and academic customers.
  • skrinings.lv Online health platform developed by Longenesis specialists that empowers individuals to learn about their health, particularly breast cancer risks and contraception methods, through tools such as a breast cancer risk assessment test. Integrates with Dante Genomics to offer discounted whole genome sequencing. Targeted at individual consumers seeking self-administered health screening.

Quantifiable outcome

  • 500,000+ citizens participated in Emirati Genome Programme with Longenesis tools since 2020, expected to reach 1 million by 2025
  • +2 more outcomes

Companies that use Longenesis

Customer profile

Named customers11 records

Segments6 records

Ideal customer profiles4 records

Longenesis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Longenesis partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and flagship.

  • Dante GenomicscoreStrategic or Co-development Partner · 1 November 2022Partnership to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants across the Baltics and Mediterranean regions. Dante Genomics provides at-home blood collection kits for WGS and genomic reports, while Longenesis enriches its digital educational engagement platform with discounted Dante offerings. The collaboration aims to make personalized medicine more mainstream across Europe.
  • M42 Health (formerly G42 Healthcare)flagshipStrategic or Co-development Partner · 1 January 2020Partnership with M42 Health for the Emirati Genome Programme aims to create one of the world's largest patient biobanks. Longenesis provides digital tools for participant engagement and consent-driven medical research, while M42 Health contributes AI-powered healthcare capabilities and genomic sequencing expertise. The collaboration supports UAE's national genome initiative with over 500,000 citizens participating since 2020.
  • MedtroniccoreStrategic or Co-development PartnerCollaboration with Medtronic for implementing patient engagement solutions. Longenesis tools have impacted the speed of patient enrolment while complying with highest requirements of safety, data protection and participant-centricity. The partnership focuses on market access and patient enrollment for medical device research.
  • EwopharmacoreStrategic or Co-development PartnerPartnership with Swiss pharmaceutical company Ewopharma for observational multicenter clinical trial into respiratory tract infections in children. Longenesis provides digital engagement tool, e-consent, patient diary and reminder functionality through its Engage platform to streamline data collection for investigators and participants' parents.
  • Gedeon RichtercoreStrategic or Co-development PartnerPartnership with Hungarian pharmaceutical company Gedeon Richter for Real-World Data study on contraception. Longenesis.Curator platform enabled quick patient identification fitting inclusion criteria within existing cohort and immediate invitation sending for study participation.
  • Riga Technical UniversitycoreStrategic or Co-development PartnerResearch partnership with Riga Technical University for cardiometabolic disease digital platform project. EU Cohesion Policy funded project 1.1.1.3/1/24/A/090 developing cloud-based module for cardiometabolic disease prevention and early diagnosis.
  • Pauls Stradiņš Clinical University HospitalcoreStrategic or Co-development PartnerOngoing research collaboration with Pauls Stradiņš Clinical University Hospital on multiple projects including cardiometabolic disease prevention platform and DiaBuddy digital assistant for Type 1 diabetes patients.
  • MEDONcoreStrategic or Co-development PartnerPartnership with MEDON for developing modular digital platform for clinical observations and research in cardiology. Project F-DIGIT-4 focuses on study design creation, patient engagement, and data analysis functionality.
  • Children's Clinical University Hospital (Latvia)coreStrategic or Co-development PartnerLong-term collaboration for patient surveys, long COVID symptom tracking in children, and PREM data gathering. Hospital has been using Longenesis digital tools for over a year with positive feedback on availability, speed, and development.
  • Riga Stradiņš UniversitycoreStrategic or Co-development PartnerAcademic partnership for Myasthenia gravis digital registry transformation and other research projects including rare skin diseases registry with Department of Atomic Physics and Spectroscopy.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Longenesis competitors and assessment

Company assessment

Direct peers

  • Castor: Castor is a direct competitor offering an eClinical platform for decentralized and hybrid clinical trials, including eConsent, ePRO, and remote data capture. It overlaps directly with Longenesis Engage on patient engagement and consent management in clinical research.
  • Medable: Medable provides a decentralized clinical trial platform with eCOA, eConsent, telehealth, and patient engagement tools. It competes head-to-head with Longenesis Engage for the same life sciences and CRO buyers running modern clinical studies.
  • Signant Health: Signant Health specializes in clinical trial patient engagement, eCOA, ePRO, and rater training. Its product set directly competes with Longenesis Engage for pharma and CRO customers running patient-centric studies.
  • TriNetX: TriNetX operates a global health research network that enables cohort identification and real-world data queries for clinical trial feasibility. It is the most direct competitor to Longenesis Curator for sponsor and CRO cohort discovery.

Broad incumbents

  • Veeva Systems: Veeva offers a broad suite of cloud software for life sciences, including Vault Clinical (EDC, CTMS, eTMF) and CRM. It is a broad incumbent whose Vault platform can absorb functionality that overlaps with both Engage and Curator.
  • Medidata (Dassault Systèmes): Medidata is a leading clinical trials technology platform covering EDC, CTMS, eCOA, randomization, and trial design. It is a broad incumbent whose Rave platform competes with Longenesis across the full clinical operations stack.
  • Oracle Clinical One: Oracle's Clinical One platform is a unified clinical trial suite covering EDC, RTSM, eCOA, and patient engagement. It competes as a broad incumbent offering an end-to-end alternative to Longenesis's two-product approach.
  • IQVIA: IQVIA combines clinical research services with technology platforms (e.g., EDC, eCOA, real-world data) and operates a large healthcare data network. It is a broad incumbent whose analytics and data network partially overlap with Curator's data discovery use cases.

Emerging players

  • Y-Prime: Y-Prime provides clinical trial technology, including IRT, eCOA, and patient engagement tools, focused on simplifying trial operations. It is an emerging peer with overlapping capabilities to Longenesis Engage in the patient engagement and data collection layer.
  • Florence Healthcare: Florence Healthcare provides an eRegulatory and site document management platform for clinical trials. While narrower than Longenesis, it competes in the same site- and study-management buying cycle that Longenesis targets with its research workflow tools.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Longenesis social profiles

Digital presence

Longenesis compliance and trust

Trust signal

Compliance3 records

Longenesis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Longenesis leadership team

Management profile

Number of profiles

Profiles9 records

Longenesis funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Longenesis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longenesis

What does Longenesis do?

Longenesis provides a dual SaaS platform ecosystem for biomedical research and patient engagement. Engage is a digital patient engagement platform offering dynamic consent management, surveys, screening, PROMs/PREMs collection, patient diaries, and risk stratification tools. Curator is a biomedical research acceleration platform that lets biobanks, registries, and hospitals publish anonymised dataset metadata and enables researchers to query, identify patient cohorts, and request collaborations in real time, while preserving patient privacy and GDPR compliance.

Is Longenesis a public or private company?

Longenesis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Longenesis founded?

Longenesis was founded in 2018. It employs 11 to 50 people.

Where is Longenesis based?

Longenesis is headquartered in Riga, Latvia, in the Europe region.

How does Longenesis make money?

One revenue line is on record: saaS Platform Subscriptions.

Who are Longenesis's main competitors?

Direct peers on record are Castor, Medable, Signant Health and TriNetX. Broad incumbents are Veeva Systems, Medidata (Dassault Systèmes), Oracle Clinical One and IQVIA. Emerging players are Y-Prime and Florence Healthcare.

Does Longenesis have an API?

No public API is recorded for Longenesis.

What industry is Longenesis in?

Longenesis's product category is Clinical Trial Technology / Healthcare Research Software. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLALABAJ, Patient Engagement, Education & Messaging Platforms (portal/CRM integrated). Its NAICS code is 513210 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TmcnetLatvian startup dominates Supernova Challenge 2.0 with $100,000 victory for its innovative Health Tech solutionsLatvian health tech startup Longenesis won $100,000 at the Supernova Challenge 2.0, a global startup pitch competition. The platform facilitates secure data exchange between life-science companies, healthcare providers, and patients, and has impacted over 850,000 patients across the EU and MENA regions.PR NewswireLatvian startup dominates Supernova Challenge 2.0 with $100,000 victory for its innovative Health Tech solutionsLatvian health tech startup Longenesis won the top prize of $100,000 at the Supernova Challenge 2.0, which concluded at Expand North Star in Dubai. The competition featured over 650 startups from 69 countries, with AI, SaaS, and healthcare as top sectors. Longenesis plans to scale up, especially in the Gulf region.PR NewswireLatvian startup dominates Supernova Challenge 2.0 with $100,000 victory for its innovative Health Tech solutionsLatvian health tech startup Longenesis won the $100,000 top prize at the Supernova Challenge 2.0, which concluded at Expand North Star in Dubai. The competition featured over 650 startups from 69 countries, with AI, SaaS, and healthcare as top sectors. Longenesis plans to scale up, especially in the Gulf region.LiaaLatvian startup Longenesis dominates Supernova Challenge 2.0 with $100,000 victoryLatvian health tech startup Longenesis won the $100,000 grand prize at the Supernova Challenge 2.0 held during Expand North Star in Dubai. The competition, organized by Dubai World Trade Centre and hosted by the Dubai Chamber of Digital Economy, featured over 1,800 startups and attracted significant global participation with a focus on AI, SaaS, and healthcare sectors.ForbesMeet A VC On A Mission To Support Women In LongevityGarri Zmudze, founding partner of LongeVC, discusses the importance of supporting women-led longevity companies, citing a 2020 statistic that only 40% of delegates at the Aging Research and Drug Discovery conference were women. He highlights women-led startups like AOA Dx, Longenesis, and Marble Therapeutics, and advocates for more diversity in longevity investing.DELFIPasaules Uzņēmējdarbības kausā Latviju pārstāvēs jaunuzņēmums 'Longenesis'Longenesis, a Latvian health-tech startup, won the Entrepreneurship World Cup national final, earning a spot in the global final in Riyadh. The company will attend online training and mentoring sessions to prepare for the November global final, where it competes for a $1 million prize.Eng.lsm.lvBiotech firm Longenesis wins Latvian entrepreneurship awardLongenesis, a Latvian health-tech start-up, won the Latvian national finals of the Entrepreneurship World Cup on 25 August, earning a ticket to the global finals in Riyadh. The winner also received participation in the EWC Accelerator and mentoring. Longenesis will compete against winners from 200 countries for a top 100 spot.LA.LVPasaules Uzņēmējdarbības kausā Saūda Arābijā, kur balvu fonds ir miljons ASV dolāru, mūsu valsti pārstāvēs “Longenesis” no RīgasRiga-based health-tech startup Longenesis won Latvia's national final of the World Business Cup, earning a spot in the Riyadh final with a one-million-dollar prize pool. The global final is set for November 2022, and the winner will receive a WebSummit invitation and accelerator access.Emerging EuropeMade in Emerging Europe: Skeleton Technologies, Rohlik, 10Lines, Longenesis, AerinXEmerging Europe's start-ups raised significant funding: Skeleton Technologies got a 29 million euro Series D, Rohlik raised 100 million euros to become a unicorn, 10Lines secured 700,000 euros, Longenesis received one million euros, and AerinX partnered with VD Gulf. The companies span energy storage, grocery delivery, robotics, biomedical research, and aircraft maintenance.Longevity.TechnologyLongevity start-up Longenesis raises $1.2m seed fundLatvia-based Longenesis raised $1.2 million in a late seed round led by Rustam Gilfanov, with participation from Ilya Suharenko. The funds will support expansion and scaling of its patient engagement and data curation tools, including a Medtronic pilot. The company aims to accelerate biomedical research through compliant data access.